Magnesium Sulfate and Postoperative Hypercoagulability in Laparoscopic Gynecological Surgeries

NCT ID: NCT06717490

Last Updated: 2024-12-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-12-31

Study Completion Date

2025-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This will be a prospective randomized, double-blind study, aiming at investigating the effects of magnesium sulfate on postoperative hypercoagulability in patients undergoing laparoscopic gynecological surgeries under general anesthesia

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This randomized, double-blind, controlled study investigates the effects of magnesium sulfate on postoperative hypercoagulability in patients undergoing laparoscopic gynecological surgeries under general anesthesia. Using thromboelastometry, the study aims to assess the impact of magnesium sulfate on blood coagulation parameters. Patients are divided into two groups, with one group receiving magnesium sulfate and the other receiving normal saline. Both patients and investigators are blinded to the treatment allocation. The study will analyze clotting time, clot formation, and coagulation markers to evaluate the therapeutic potential of magnesium sulfate in reducing postoperative hypercoagulability.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Magnesium Sulfate Thromboelastometry

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Patients are divided into two groups, with one group receiving magnesium sulfate and the other receiving normal saline.
Primary Study Purpose

OTHER

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MS group

The patients allocated to this group will receive an intravenous bolus of magnesium sulfate (50 mg/kg) followed by a continuous infusion (15 mg/kg/h) Blood coagulation parameters will be assessed pre- and post- magnesium administration using thromboelastometry.

Group Type ACTIVE_COMPARATOR

Magnesium sulphate

Intervention Type DRUG

In patients allocated to the MS group, a fixed dose of magnesium sulfate diluted in a fixed volume of natural saline will be administered intravenously.

Thromboelastometry will be performed pre and post magnesium administration.

NS group

The patients allocated to this group will receive an equivalent volume of normal saline proportionally to the active comparator group. Blood coagulation parameters will be assessed pre- and post-magnesium administration using thromboelastometry.

Group Type PLACEBO_COMPARATOR

Placebo Drug

Intervention Type OTHER

In patients allocated to the NS group, a fixed dose of natural saline will be administered intravenously, through a fixed volume of solution.

Thromboelastometry will be performed pre and post magnesium administration.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Magnesium sulphate

In patients allocated to the MS group, a fixed dose of magnesium sulfate diluted in a fixed volume of natural saline will be administered intravenously.

Thromboelastometry will be performed pre and post magnesium administration.

Intervention Type DRUG

Placebo Drug

In patients allocated to the NS group, a fixed dose of natural saline will be administered intravenously, through a fixed volume of solution.

Thromboelastometry will be performed pre and post magnesium administration.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Thromboelastometry Thromboelastometry

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ASA I and II patients
* Laparoscopic gynecological surgeries
* age \>18 years
* Patients receiving prophylactic anticoagulant therapy 12 hours before surgery based on the Caprini score
* Patients receiving prophylactic anticoagulant therapy 12 hours postoperatively based on the Caprini score.

Exclusion Criteria

* ASA ≥ III
* age \<18 years
* BMI \>40 kg/m²
* Pregnancy
* Known hematologic disorders
* Liver/kidney/cardiovascular disease
* Severe anemia (6,5- 7,9 g/dl)
* Inability or refusal to provide informed consent
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Aretaieion University Hospital

OTHER

Sponsor Role collaborator

Marianna Mavromati

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Marianna Mavromati

Marianna Mavromati, MD, Principal Investigator and Anesthesiology Resident, Aretaieion University Hospital, NKUA

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kassiani Theodoraki, Professor

Role: STUDY_CHAIR

Aretaieio University Hospital, National and Kapodistrian University of Athens

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Aretaieion University Hospital

Athens, Attica, Greece

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Greece

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Marianna Mavromati, MD

Role: CONTACT

Phone: 0030 6975630647

Email: [email protected]

Kassiani Theodoraki, Professor

Role: CONTACT

Phone: 00306974634162

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Marianna Mavromati, MD

Role: primary

Marianna Mavromati, MD

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

619/05-11-2024

Identifier Type: -

Identifier Source: org_study_id